Bavarian Nordic A/S is a fully integrated biotechnology company that develops and manufactures vaccines for infectious diseases and public health preparedness. The company's commercial portfolio includes proprietary vaccines for smallpox and mpox (JYNNEOS/IMVANEX/IMVAMUNE), as well as acquired travel vaccines for rabies (Rabipur/RabAvert), tick-borne encephalitis (Encepur), cholera (Vaxchora), and typhoid (Vivotif). Bavarian Nordic utilizes advanced technologies, such as viral vectors and virus-like particles, to develop its pipeline of novel vaccine candidates. The company operates manufacturing facilities in Denmark and Switzerland, alongside research and development sites in Germany. Its primary customers include national governments, military organizations, and public health agencies that stockpile vaccines for emergency preparedness, as well as the commercial travel health market.
